Question explored with the scientific record
Tell me about DMSO for optical cataracts
The short version: no retrieved study tested DMSO for cataracts in humans or animals, so there is no evidence to ground a claim of benefit or harm for that specific use.
The evidence we retrieved covers DMSO as a topical anti-inflammatory and penetration enhancer for skin conditions [5], a cryoprotectant for cells [4], a chemical chaperone for protein-aggregation diseases [2], and a solvent in lab chemistry [1]. None of these records involve the eye, the lens, or cataract formation. The closest match is a 1998 study of topical DMSO for skin amyloidosis [3], which is a different tissue and a different disease mechanism.
DMSO is a powerful solvent that penetrates skin and mucous membranes rapidly. It can carry other substances with it and can disrupt lipid bilayers at high concentrations [5]. Applied to the eye, those properties could theoretically affect lens proteins or the glycocalyx of the corneal endothelium, but no study in this retrieval tested that. The safety data here comes from topical skin use and intravenous infusion of cryopreserved cells [4], not from ocular application.
My call: there is no evidence in this retrieval to support or oppose using DMSO for cataracts. The question has not been studied in the records we found. Confidence: not clear — the retrieval simply does not cover this question.
Sources used 5
-
Microwave-assisted photooxidation of sulfoxides
Ethynylbenzene-catalyzed photooxidation of sulfoxides to sulfones is enhanced by microwave irradiation, which appears to prolong the photosensitizer triplet state and enable higher yields than conventional heating, revealing a non-thermal microwave effect in organic photochemist…
DOI: 10.1038/s41598-021-99322-9 -
Chemical Chaperones Reduce Aggregate Formation and Cell Death Caused by the Truncated Machado–Joseph Disease Gene Product with an Expanded Polyglutamine Stretch
This study investigates the effects of chemical chaperones, specifically dimethyl sulfoxide (DMSO), glycerol, and trimethylamine N-oxide (TMAO), on reducing aggregate formation and cell death caused by the truncated ataxin-3 protein associated with Machado-Joseph disease, sugges…
DOI: 10.1006/nbdi.2002.0502 -
Intermittent use of topical dimethyl sulfoxide in macular and papular amyloidosis
This study investigates the efficacy of intermittent topical dimethyl sulfoxide (DMSO) therapy in patients with macular and papular amyloidosis, demonstrating significant clinical improvement in pruritus and papule flattening while tolerating side effects better than with daily …
DOI: 10.1046/j.1365-4362.1998.00600.x -
Dimethyl sulfoxide in cryopreserved mesenchymal stromal cell therapy products: is there a safety risk to patients?
This study reviews published safety data on dimethyl sulfoxide (DMSO) used as a cryoprotectant in DMSO-containing cryopreserved mesenchymal stem/stromal cell (MSC) products administered intravenously or topically, evaluating patient safety risks and concluding no significant saf…
DOI: 10.1186/s12967-025-06807-6 -
Dimethyl sulfoxide in topical pharmaceutical drug development: A fresh perspective
A narrative review proposes that high-purity (>99.99%) DMSO is an effective, underused topical penetration enhancer with anti-inflammatory and analgesic activity, and that higher purity may reduce the halitosis historically associated with topical DMSO.
DOI: 10.66617/001c.120609